Scientists hunt for genetic signs to personalize bile duct cancer therapy
NCT ID NCT06648057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls 100 adults with advanced biliary tract cancer who are already scheduled to receive a combination of two drugs (lenvatinib and pembrolizumab). Researchers will collect blood and tumor samples to look for genetic markers that might predict who responds best to treatment. The goal is to understand why some patients benefit more than others, not to test a new treatment directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bundang CHA Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?